drugset / Trial / NCT03919500
Erythropoietin Protects Very Preterm Infants Against Necrotizing Enterocolitis
Phase 2
Completed
1285 enrolled
Zhengzhou University
Göteborg University · collabThe First Affiliated Hospital of Zhengzhou University · collabWomen and Children Health Care Center of Luoyang, China · collabZhengzhou Children's Hospital, China · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This study evaluates the effect of repeated low-dose erythropoietin (EPO) treatment on necrotizing enterocolitis (NEC) in very preterm infants. Half of participants will receive EPO, while the other half will receive a placebo.
Timeline
- Start
- 2014-01
- Primary completion
- 2019-04
- Completion
- 2019-04
Publications
- Sun H, Song J, Kang W, Wang Y, Sun X, Zhou C, Xiong H, Xu F, Li M, Zhang X, Yu Z, Peng X, Li B, Xu Y, Xing S, Wang X, Zhu C. Effect of early prophylactic low-dose recombinant human erythropoietin on retinopathy of prematurity in very preterm infants. J Transl Med. 2020 Oct 19;18(1):397. doi: 10.1186/s12967-020-02562-y.
- Wang Y, Song J, Sun H, Xu F, Li K, Nie C, Zhang X, Peng X, Xia L, Shen Z, Yuan X, Zhang S, Ding X, Zhang Y, Kang W, Qian L, Zhou W, Wang X, Cheng X, Zhu C. Erythropoietin prevents necrotizing enterocolitis in very preterm infants: a randomized controlled trial. J Transl Med. 2020 Aug 8;18(1):308. doi: 10.1186/s12967-020-02459-w.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | epoetin alfa | Protein / enzyme biologic | 500 iu/kg | Intravenous |